Wells Fargo raises CBOE Holdings price target to $357 on estimates

Wells Fargo raised its CBOE price target to $357 from $309, maintained Equal Weight, and lifted its 2027 and 2028 EPS estimates to $15.50 and $17.10, respectively—1.7% and 2.6% above consensus. The firm cites stronger index volumes, access fees and interest income, partly offset by lower multi-listed capture and higher expenses; CBOE’s approximately $1 billion buyback authorization adds repurchase capacity, with Wells Fargo modeling about $500 million in 2027. Separately, Cboe reported Q3 2026 adjusted EPS of $3.63 versus $3.42 expected and revenue of $712.2 million versus $707.3 million expected.

Analysis

The target’s apparent upside is predominantly a valuation call, not an earnings reset: using the supplied figures, the share price is about 17x Wells Fargo’s 2027 EPS estimate, versus 23x in its target framework. The EPS revision is modest, so the key question is whether investors will pay a higher multiple for sustained growth—not whether a few cents of estimate changes justify the target. Treat the target as a scenario, not a catalyst.

Cboe’s earnings mix creates cross-currents: stronger index activity can lift transaction revenue, while weaker multi-listed capture signals competitive pressure that may persist even if volumes rise. Nasdaq, ICE and other options venues are relevant competitive checks; market-wide volume growth alone would not prove Cboe is gaining share. Lower assumed S&P royalty step-up also makes index-licensing economics a watch item, while interest income could soften if rates decline. Buybacks may support per-share results, but only executed repurchases—not authorization capacity—affect the share count.

Over days, the analyst revision may reinforce positive sentiment, but the price already needs a substantial multiple expansion to reach the target. Over 1–3 months, monitor options market share/capture, index activity, operating expenses and realized repurchases. Over 6–18 months, the thesis depends on durable licensing economics and volume growth outweighing capture erosion and expense growth. Falsify the bull case if subsequent results show weakening capture, expense growth outrunning revenue, or estimate cuts; a lower S&P royalty outlook would further pressure the rerating case.

Key Decisions for Investors

• Consider a staged, modest long CBOE rather than buying solely on the target: entry is more compelling after a pullback or when results confirm improving capture and expense discipline. The upside case requires multiple expansion; size for that valuation risk, not just the estimate revisions.
• Track the next quarterly disclosures for multi-listed capture/share, index volumes, operating-expense growth, and actual buybacks. If volume rises but capture continues to deteriorate, do not treat headline activity growth as confirmation.
• Keep a relative-value watch on Cboe versus Nasdaq and ICE rather than initiating a pair trade without current valuation and segment data. Evidence of share loss or weaker licensing economics would favor reducing CBOE exposure; stable capture and controlled costs would strengthen the long thesis.